483
Celgene Corp., d.b.a. Abraxis BioScience LLCFDA 483 - Celgene Corp., d.b.a. Abraxis BioScience LLC - February 26, 2009
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
Abraxis Bioscience in Melrose Park, IL, was cited for significant quality control and reporting deficiencies during an FDA inspection. The firm released drug products that failed visual particulate specifications and conducted insufficient investigations into customer complaints regarding foreign particulate matter in distributed Abraxane vials. Additionally, the company failed to submit required NDA-Field Alert Reports for these serious product quality issues.
- Inspection Date
- February 26, 2009
- Product Type
- Drugs
Open in Dashboard
ID · f5491464-860c-4259-a49b-d2b1fd45534f